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Abstract
We investigated the molecular epidemiology and population dynamics of HCV infection among 
indigenes of two semi-isolated communities in North-Central Nigeria. Despite remoteness and 
isolation, ~15 % of the population had serological or molecular markers of hepatitis C virus 
(HCV) infection. Phylogenetic analysis of the NS5b sequences obtained from 60 HCV-infected 
residents showed that HCV variants belonged to genotype 1 (n=51; 85 %) and genotype 2 (n=9; 
15 %). All sequences were unique and intermixed in the phylogenetic tree with HCV sequences 
from people infected from other West African countries. The high-throughput 454 pyrosequencing 
of the HCV hypervariable region 1 and an empirical threshold error correction algorithm were 
used to evaluate intra-host heterogeneity of HCV strains of genotype 1 (n=43) and genotype 2 
(n=6) from residents of the communities. Analysis revealed a rare detectable intermixing of HCV 
intra-host variants among residents. Identification of genetically close HCV variants among all 
known groups of relatives suggests a common intra-familial HCV transmission in the 
communities. Applying Bayesian coalescent analysis to the NS5b sequences, the most recent 
common ancestors for genotype 1 and 2 variants were estimated to have existed 675 and 286 years 
ago, respectively. Bayesian skyline plots suggest that HCV lineages of both genotypes identified 
in the Nigerian communities experienced epidemic growth for 200–300 years until the mid-20th 
century. The data suggest a massive introduction of numerous HCV variants to the communities 
during the 20th century in the background of a dynamic evolutionary history of the hepatitis C 
epidemic in Nigeria over the past three centuries.
INTRODUCTION
Hepatitis C virus (HCV) infection is a serious public health problem worldwide. HCV 
causes chronic infection in 70–80 % of infected people. Chronic HCV infection may 
progress to chronic hepatitis and cirrhosis, leading in many cases to severe complications 
including hepatocellular carcinoma (HCC) and death (Itskowitz, 2007). An estimated 170 
million people or ~3 % of the world’s population are chronically infected with HCV; and 3–
4 million people are newly infected each year, with most of these cases occurring in Africa 
(EASL, 1999; WHO, 1999).
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HCV is a positive-strand, ssRNA virus classified in the genus Hepacivirus of the family 
Flaviviridae (Shepard et al., 2005). The HCV genome consists of ~9600 nt and encodes a 
single long polyprotein with the following gene order: 5′-C-E1-E2-p7-NS2-NS3-NS4A-
NS4B-NS5A-NS5B-3′ (Lindenbach & Rice, 2005). The HCV genome displays considerable 
sequence divergence. HCV has been classified into six genotypes, 1–6, with each genotype 
further subdivided into subtypes displaying different geographical distributions worldwide 
(Simmonds et al., 2005). For example, HCV subtype 5a and all subtypes of genotype 6 are 
mainly restricted to South Africa and South East Asia, respectively (Simmonds et al., 1993), 
while subtypes 1a, 1b, 2b and 3a are distributed globally (Smith et al., 1997). A new 
genotype 7 has been recently registered in the HCV databases, but the full report on this 
isolate has not been published (Nakano et al., 2012).
In Africa, divergent strains of HCV genotypes 1 and 2 were found in Ghana, Guinea 
Conakry, Burkina Faso, Benin Republic and Guinea Bissau, suggesting that these strains 
have been endemic in the West African subregion (Candotti et al., 2003; Jeannel et al., 
1998; Markov et al., 2009; Ruggieri et al., 1996; Wansbrough-Jones et al., 1998). Recently, 
analysis of the epidemic history of HCV infections traced the modern HCV lineages in West 
Africa back to the 17th–20th centuries (Markov et al., 2009; Pouillot et al., 2008b). This 
estimate, however, does not take into account Nigeria, the country with more than three-
quarters of the population of West Africa, which occupies a geographically central position 
within this African subregion. Identifying HCV circulating in Nigeria is important for 
guiding HCV infection control initiatives, understanding the evolutionary dynamics and 
natural history of HCV infection among indigenous West Africans, and predicting the future 
burden of HCV-related disease in Africa.
The epidemiology of HCV infection in Nigeria is not well understood. Most studies of 
hepatitis C in Nigeria have focused on serological characterization of selected population 
groups, e.g. prison inmates, patients with diabetes mellitus, blood donors, HIV-infected 
persons, patients with chronic renal failure and those with sickle cell anaemia, for whom risk 
for HCV infection in urban areas of Nigeria is variable. Previous studies established a broad 
HCV-seroprevalence rate, ranging from 1.9 % among pregnant women in Benin City to 
~14.5 % among apparently healthy individuals with a family history of diabetes in Plateau 
State or among HIV-positive patients in Lagos (Balogun et al., 2010; Nwankiti et al., 2009; 
Onakewhor & Okonofua, 2009). HCV infections have been shown to play a significant role 
in the aetiology of chronic liver disease and HCC in Nigeria (Laraba et al., 2010; Mustapha 
et al., 2007). Despite HCV endemicity, association with HCC and importance of HCV 
genotypes for clinical management (Hnatyszyn, 2005; Zeuzem, 2004), only three small-
scale studies have been made to genetically characterize HCV isolates from Nigeria 
(Agwale et al., 2004; Mellor et al., 1995; Oni & Harrison, 1996). As a result, an extremely 
limited number of HCV sequences from Nigeria are available in any repository of nucleotide 
sequences. Genotype distribution and genetic characterization of HCV strains circulating in 
different African countries, including Nigeria, are critical for designing universally 
efficacious vaccines against HCV infection, predicting the sensitivity of diagnostic assays 
and understanding the evolutionary history and molecular epidemiology of HCV in Africa.
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Here, we present the first comprehensive phylogenetic and evolutionary analysis of HCV 




Samples (n=519) were collected from the study sites (341 from village 1 and 178 from 
village 2) and tested for anti-HCV and for HCV RNA by the NS5b real-time PCR. A total of 
73 samples (55 from village 1 and 18 from village 2) were found to be anti-HCV-positive 
and 60 samples were PCR-positive (47 samples from village 1, 13 from village 2), with 55 
samples being both anti-HCV- and PCR-positive. Thus, a total of 78 samples were identified 
that had serological or molecular markers of HCV infection. An overall high prevalence of 
15 % of HCV infection in these communities represents one of the highest estimates 
reported in Nigeria (Balogun et al., 2010; Nwankiti et al., 2009; Onakewhor & Okonofua, 
2009). Of the 60 PCR-positive individuals, males (n=33) and females (n=27) were almost 
equally represented. Although, the anti-HCV seroprevalence was slightly higher in men than 
women (sex ratio=1.2), this difference is not statistically significant. The majority (63.3 %) 
of the infection was found in individuals between the ages of 20 and 40 years.
Phylogenetic relationships among HCV variants
Considering the rural location and relative isolation, it was expected that these two small 
communities would have limited exposure to HCV and should have had a single or only a 
few HCV strains circulating among the indigenous residents. However, analysis of the NS5b 
sequences identified HCV variants belonging to genotypes 1 (n=51; 85 %) and 2 (n=9; 15 
%) (Fig. 1). Furthermore, all genotype 1 and 2 variants segregated into subtypes, some of 
which were not previously characterized (Fig. 1). These findings indicate that the two 
communities were infected with several HCV strains, suggesting either numerous exposures 
or exposure to all these HCV lineages in bulk from limited infection events.
The number of HCV genotype 1 variants in these communities was fivefold greater 
compared with the number of genotype 2 variants. The NS5b sequence analysis did not 
reveal any community-specific clustering and showed extensive phylogenetic intermixing of 
these sequences with other HCV isolates from different African countries and strains found 
worldwide. Consistent with the NS5b phylogenetic analysis, genetic diversity of 17.3 and 
16.2 % was observed for the genotype 1 and 2 variants, respectively. The high genetic 
diversity suggests a long evolutionary history. However, the presence of two genotypes and 
several subtypes as well as intermixing with HCV variants found worldwide strongly 
suggest that many, if not all, of these variants were introduced rather than evolved in the two 
communities. Although many variants could not be classified into any known subtype, there 
was a trend for the variants to form clusters.
HCV variants from West and Central Africa
The diversity of the HCV variants observed in the two communities was compared to HCV 
genotype 1 and 2 strains identified in other West and Central African countries (Fig. 2). 
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HCV NS5b sequences from Central Africa had the tendency to form compact and distinct 
clusters. A few of these sequences intermixed with sequences from West Africa (Fig. 2). It 
should be noted, however, that among 141 sequences from Central Africa, 136 were 
obtained from Cameroon, with only five sequences being from two immediate neighbouring 
countries (Table 1). Conversely, 107 sequences from West Africa originated from six 
countries within the West African subregion (Table 1). These sequences were more diverse 
and grouped with many of the variants determined in this study, thus indicating a genetic 
relatedness of HCV variants identified among the two communities and HCV strains 
broadly circulating in West Africa. However, the distribution of HCV variants between 
genotypes 1 and 2 in these communities in Nigeria is very different from the other West 
African countries. In the Nigerian communities, 85 % of HCV variants belong to genotype 
1, while only 15 % of HCV variants recovered from the other West African countries belong 
to this genotype.
Intra-host HCV heterogeneity
The presence of two HCV genotypes, several classified/ unclassified subtypes and numerous 
HCV variants raise questions about the origin and maintenance of HCV diversity in these 
two communities. To investigate genetic connections among these variants in the 
population, quasispecies analysis of HVR1 was conducted using high-throughput 
pyrosequencing of 43 HCV genotype 1 and six genotype 2 samples. The small size of the 
communities and circulation of many HCV variants suggests a potential for frequent mixed 
infections. However, analysis of quasi-species revealed a very limited intermixing of HCV 
quasi-species among residents (Figs 3 and 4).
There were six groups of relatives included in the analysis: group 1 – kng005 (20 years, 
female), kng006 (40 years, male) and kng007 (33 years, female); group 2 – kng021 (22 
years, male), kng022 (45 years, male), kng23 (14 years, male) and kng024 (12 years, male); 
group 3 – kng036 (60 years, male) and kng037 (4 years, male); group 4 –kng020 (30 years, 
female) and kng59 (32 years, male); group 5 – kng025 (40 years, female) and kng026 (50 
years, female); and group 6 – kng047 (44 years, male) and kng048 (35 years, male). HCV 
intra-host variants were found clustered together among relatives within groups 1, 2, 3, 5 
and 6 (Figs 3 and 4). Although HCV variants identified from two relatives of group 4, 
kng020 and kng059, segregated into two distinct branches (Fig. 1), some intra-host variants 
found in kng020 intermixed with variants from kng059 (Fig. 3). Additionally, HCV intra-
host variants from kng020 were also found to be intermixed with variants from kng025 (Fig. 
3). These findings indicate a probable intra-familial HCV transmission or infections of 
relatives from a common source. However, clusters of genetically close intra-host variants 
were also identified among unrelated residents. For example, clusters of HCV variants from 
kng001 (15 years, male), kng002 (10 years, female), kng003 (28 years, female) and kng004 
(28 years, male), or kng031 (60 years, female), kng032 (45 years, female), kng033 (30 
years, female) and kng039 (50 years, male) were found among non-relatives. It is important 
to note that kng039 did not reside in the same community with kng031, kng032 and kng033. 
The identification of genetically close HCV variants among males and females of a broad 
age range (4–60 years) residing in different communities suggests a complex pattern of 
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HCV dissemination within the communities, with the intra-familial transmission being 
common.
Population dynamics
In order to investigate the origin and spread of HCV genotype 1 and 2 variants in these 
Nigerian communities we used the Bayesian coalescent framework implemented in BEAST. 
Each genotype was analysed separately. The inferred dates for the most recent common 
ancestor (tMRCA) for genotypes 1 and 2 were 1335 Common Era (C.E.) [95 % highest 
posterior density (95 % HPD): 1127–1529] and 1721 C.E. (95 % HPD: 1645–1791), 
respectively. Both genotypes experienced epidemic growth (Figs 5 and 6). The effective 
population size of genotype 1 increased progressively during the 18th–20th centuries and 
reached a plateau by the mid-20th century (Fig. 5). The genotype 2 expansion began during 
the mid-18th century and stabilized in the mid-20th century (Fig. 6). Genotype 2 showed a 
rapid exponential expansion between ~1920 and 1960. In support of these observations, Fu’s 
Fs test rejected the null hypothesis of neutrality and constant population for HCV genotype 
1 (P=0.0001) and genotype 2 (P= 0.0006) variants. Collectively, the data suggest that HCV 
variants of both genotypes identified in the Nigerian communities experienced population 
expansion for about 200–350 years.
DISCUSSION
Nigeria has a high burden of chronic hepatitis C and HCC associated with HCV infection 
(Balogun et al., 2010; Laraba et al., 2010; Mustapha et al., 2007; Nwankiti et al., 2009). The 
rate of HCV infection was estimated to range from 1.9 to 14.5 % in the country (Balogun et 
al., 2010; Nwankiti et al., 2009; Onakewhor & Okonofua, 2009). This study was carried out 
in two remote communities in North Central Nigeria. Despite the relative isolation of these 
communities, ~15 % of the population experienced HCV infection. The observation of the 
high HCV prevalence in the villages lends additional support to high level of endemicity of 
HCV in Nigeria.
Owing to the isolation of these small communities, it was expected that only a few HCV 
strains would have been introduced and transmitted within the population. However, 
phylogenetic analysis of the NS5b sequences from 60 isolates obtained in this study revealed 
the presence of many distinct HCV variants and subtypes belonging to genotypes 1 and 2 
(Fig. 1). HCV genotype 1 was detected in 85 % and genotype 2 in 15 % of all PCR-positive 
specimens. This finding is in agreement with three previous studies from Nigeria that 
showed predominance of HCV genotype 1, with variants of genotypes 2 and 4 being 
reported as minority genotypes (Agwale et al., 2004; Mellor et al., 1995; Oni & Harrison, 
1996).
Although isolates in this study were collected from individuals living in closed communities, 
all HCV NS5b sequences were different from each other. Phylogenetic analysis showed 
extensive intermixing of the HCV variants identified among residents of the Nigerian 
communities and reported from other countries of West Africa (Fig. 2), indicating their 
common genetic history. These findings suggest that the heterogeneous HCV variants did 
not independently evolve within these remote communities but rather were introduced. Due 
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to limited contacts with the general population, it is conceivable that few opportunities have 
been available for extraneous transmission, thus indicating that the introduction of the many 
HCV strains to the communities occurred in bulk. Alternatively, there is a remote possibility 
of the incremental introduction and accumulation of HCV variants but that would take a 
long period of time.
Analysis of HVR1 quasispecies showed that over a half of 49 HCV-infected members of the 
communities shared closely related HCV variants (Figs 3 and 4), thus revealing a complex 
pattern of potential HCV transmissions. The high HCV prevalence in these closed 
communities and the presence of many HCV lineages should have generated frequent 
opportunities for mixed infections. However, with the exception of kng020 sharing HCV 
variants with kng025 and kng059 (Fig. 3), no intermixing was observed among HCV 
quasispecies from different residents. Consistent with this finding, mixed HCV infections 
were rarely observed among such highly exposed groups as injection drug users, who 
experience only transient infections with more than one HCV variant (Viazov et al., 2000, 
2010). These observations suggest a significant interference among HCV lineages that 
thwarts their co-existence in the same host. HCV superinfection exclusion is a possible 
molecular mechanism contributing to such interference (Tscherne et al., 2007).
The principal mode of transmission resulting in such a complex pattern of transmission is 
not clear. Findings of genetically close HCV quasispecies among relatives indicate that 
intra-familial transmission is a common route of HCV spread in the communities. It was 
previously suggested that sharing of equipment used for parenteral practices is an important 
route of HCV transmission in rural regions of Africa (Ndong-Atome et al., 2009; Njouom et 
al., 2003). However, such parenteral modes as body scarification, clitodectomy using 
unsterilized instruments, circumcision, shaving by local barbers, that are known to be 
responsible for HCV transmission in Africa (Adewole et al., 2009; Ocama & Seremba, 
2011; Pépin et al., 2010), could not be responsible for the introduction of HCV genotypes 1 
and 2 strains to these villages but could play a role in maintaining modern lineages of the 
virus. We can only speculate about the possible introduction and transmission events that 
occurred many years ago.
The existence of heterogeneous HCV variants reflects a long-term presence and diversifying 
evolution of this virus, and may be associated with a particularly extensive transmission 
mode in West Africa. A high prevalence of HCV genotype 4 lineages in Egypt had been 
linked to massive treatment campaigns against schistosomiasis between 1920 and 1980 
(Frank et al., 2000). Studies from other African countries have argued that the HCV 
epidemic was driven iatrogenically, mostly by campaigns against trypanosomiasis, yaws and 
syphilis (Njouom et al., 2007; Pépin, Labbé, 2008; Pouillot et al., 2008b). Given this 
scenario, massive iatrogenic interventions could have jump-started the HCV epidemic in the 
Nigerian population. However, our data provide no direct indication on the events that could 
have led to such high prevalence of divergent HCV variants in the two communities.
Bayesian coalescence analysis indicated that the tMRCA for HCV genotype 1 and 2 lineages 
in the two Nigerian populations existed approximately 675 and 286 years ago, respectively. 
The tMRCA for genotype 1 variants identified in this study predates the tMRCA for HCV 
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genotype 1 reported globally (Ferraro et al., 2008; Lampe et al., 2010; Magiorkinis et al., 
2009; Pépin et al., 2010). This finding is consistent with many suggestions that HCV 
genotype 1 originated in Africa and spread to other parts of the world (Markov et al., 2009; 
Simmonds et al., 1993, 2005). The tMRCA for HCV genotype 2 variants found in the 
Nigerian communities is similar to the reported estimate for other countries in West Africa 
(Pouillot et al., 2008a). It should be noted, however, that analysis of sequences linked to a 
single date of collection used in this study could result in estimating tMRCA inaccurately. 
The timescale approximation for HCV epidemic may vary considerably depending on the 
estimation of evolutionary rate (Lampe et al., 2010). The rate of 5×10−4 substitutions per 
site per year used in the present analysis represents the best estimate of HCV NS5b 
evolutionary rates consistent with estimates made in several studies (Pouillot et al., 2008a; 
Pybus et al., 2001; Tanaka et al., 2002).
The Bayesian skyline plot (BSP) analysis showed that both genotype 1 and 2 populations 
experienced expansion (Figs 5 and 6). Fu’s statistical test supports this finding. HCV 
genotype 1 expansion steadily progressed for over 350 years starting in approximately 1700; 
the HCV genotype 1 population finally stabilized about the mid-20th century (Fig. 5). 
Genotype 2 expansion began in the mid-18th century and ended approximately during the 
mid-20th century (Fig. 6). A similar observation was made for genotype 2 lineages in 
Guinea-Bissau in West Africa, where the effective population size was shown to have been 
increasing from the mid-18th century. However, this growth had stabilized by approximately 
1900 (Markov et al., 2009). A trend to stabilization was also observed in the genotype 1 and 
2 BSPs at about the same time (Figs 5 and 6), indicating potential mitigation of the epidemic 
growth by the end of the 19th century. However, different from the genotype 2 expansion in 
Guinea-Bissau, both genotypes 1 and 2 in the Nigerian communities showed expansion 
before the mid-20th century (Figs 5 and 6). A similarly rapid spread of genotypes 1 and 2 
from 1920 to 1950 was also observed in neighbouring Cameroon in Central Africa (Markov 
et al., 2009). However, this spread was not preceded by epidemic growth as seen in this 
study. Thus, the Nigerian expansion seems to combine the growth patterns observed in West 
and Central Africa. During the colonial period, in French speaking areas in Central Africa, 
unsafe injections practised mostly by mobile medical units for the prevention of sleeping 
disease early in 20th century were most probably responsible for the rapid HCV expansion 
in Cameroon (Njouom et al., 2007; Pouillot et al., 2008b). In English-speaking areas in 
West Africa including Nigeria, medical services have been broadly provided preferentially 
in stationary facilities since the 19th century (Millar & Foege, 1969) and could have 
contributed to the expansion during the 19th and mid-20th centuries in Nigeria through 
unsafe injection practices.
We have recently detected a population expansion of HBV genotype E lineages in these 
Nigerian communities (Forbi et al., 2010). Strikingly, this expansion occurred during 
approximately 1970–1980 or approximately 20 years later than the HCV expansion detected 
here. The tMRCA for the modern HBV genotype E was predicted to have existed 
approximately in the mid-20th century. The cause for this difference in time of expansion 
between two viral pathogens that share modes of transmission and co-circulate in the same 
communities is unknown. The difference in tMRCA indicates that the HCV genotype 1 and 
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2 lineages are much older than HBV genotype E (Forbi et al., 2010). It is conceivable that 
the epidemiological processes responsible for the origination of the modern HBV genotype 
E lineages (Forbi et al., 2010) could have contributed to the continuation of expansion of the 
already abundant HCV variants during the mid-20th century.
Six of the nine HCV genotype 2 variants identified in the Nigerian communities share a 
single branch of the phylogenetic tree with the major cluster of the variants from Cameroon, 
indicating a strong genetic connection between the genotype 2 strains circulating in both 
countries. These variants represent a subset of all genotype 2 lineages identified in West 
Africa (Figs 1 and 2). Recently, it was suggested that the genotype originated in West Africa 
and spread from the most western part of this region toward the centre of the continent 
(Markov et al., 2009; Ndjomou et al., 2003; Pouillot et al., 2008b). The detection of genetic 
similarity between the predominant genotype 2 lineages in Nigeria and Cameroon is 
consistent with this hypothesis and further suggests that the genotype 2 strains were filtered 
through Nigeria before reaching Cameroon. Nigeria contributes over three-quarters of the 
population in West Africa and is a convergence point and centre for active population 
mixing in Africa. Owing to its geographical location and population density, Nigeria may 
have critically facilitated HCV transmission from West to Central Africa.
The data suggest that these two Nigerian communities have experienced a massive 
introduction of multiple HCV variants, which probably occurred around the mid-20th 
century. The extensive genetic variation among HCV variants observed in this study 
indicates that the introduction was rather recent because genetic drift would have reduced 
the number of HCV variants circulating in these small communities over an extended period 
of time spanning more than one human generation. The prevalence of ~15 % is among the 
highest reported in West and Central Africa (Bekondi et al., 2010; Nagalo et al., 2011). 
Whether the prevalence and HCV genetic composition in these two communities represents 
the HCV population circulating in Nigeria as a whole needs further enquiry. This study is 
the first comprehensive investigation of the epidemic history of HCV in Nigeria revealing 
significant variation in the evolutionary histories of HCV genotypes 1 and 2 in two remote 
Nigerian villages that could be critical to understanding the dynamics of the diversity and 
spread of HCV in West and Central Africa.
METHODS
Ethics statement
Written informed consent was obtained from all participants involved in this study. The use 
of specimens in this study was approved by the Institutional Review Board (IRB) of the US 
Centers for Disease Control and Prevention and the Nigerian Federal Ministry of Health.
Serum samples and serological testing
A total of 519 blood samples were randomly obtained in 2007 from asymptomatic indigenes 
of two small rural communities in Keffi local government area of Nasarawa state in Nigeria, 
with 341 samples being from village 1 and 178 from village 2. These two villages with a 
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total population of ~2000 inhabitants are ~2 miles apart. The residents have limited access to 
basic healthcare facilities.
All the studied samples were anonymous with a coding number for analysis. Samples were 
screened in the field for the presence of HCV antibodies using an immunochromatographic 
rapid assay (Shantha Biotechnics Ltd) following the manufacturer’s instructions. This assay 
uses recombinant antigen NS3, NS4 and NS5 to detect anti-HCV activity. Blood samples 
were centrifuged at 11 620 g for 10 min to separate serum from the cells. The serum samples 
were stored at − 20 °C until further testing was carried out.
Nucleic acid extraction and cDNA synthesis
Total nucleic acid was extracted from all serum specimens using the Roche MagNA Pure 
LC instrument and MagNA Pure LC Total Nucleic Acid Isolation kit (Roche Diagnostics), 
and eluted with 50 μl buffer according to the manufacturer’s instructions. RNA was 
precipitated and reverse-transcribed using both random and specific primers as described 
previously (Alter et al., 1999). Reverse transcription was carried out for 60 min at 42 °C in a 
total volume of 20 μl 5× PCR buffer (Roche), 200 pmol of each deoxynucleotide 
triphosphate, 1 μg random primers μl−1, 25 U AMV reverse transcriptase (Roche) and 40 U 
RNase inhibitor (Roche), followed by heating at 95 °C for 5 min.
Molecular detection of NS5b gene by real-time PCR
To identify HCV genotypes and subtypes, a segment of HCV NS5b encompassing positions 
8275–8616 was amplified using real-time nested PCR. All amplification reactions were 
performed using the Fast-start DNA Master plus SYBR Green 1 kit and the Stratagene 
MX3005p QPCR machine (Agilent Technologies). First-round PCR was conducted using 
primers NS5B-K1 (5′-TGGGGATCCCGTATGATACCCGC-TGCTTTGA-3′) and NS5B-
K2 (5′-GGCGGAATTCCTGGTCATA-GCCTCCGTGAA-3′). The nested reaction was 
performed with primers NS5B-122 (5′-CTCAACCGTCACTGAGAGAGACAT-3′) and 
NS5B-R1 (5′-GCTCTCAGGCTCGCCGCGTCCTC-3′). PCR included incubation at 94 °C 
for 2 min and 30 s, followed by 50 cycles of 94 °C for 20 s, 45 °C for 25 s and 72 °C for 45 
s. Nested PCRs with 45 cycles were performed using the same conditions with 2 μl of the 
first-round product diluted 1 : 100.
Sequencing of the NS5b region
Sequencing was performed using the second-round PCR products and nested primers. 
Sequencing reactions were conducted using the BigDye v3.1 chemistry sequencing kit 
(Applied Biosystems), and products were sequenced using an automated sequencer (3130xl 
Genetic Analyzer; Applied Biosystems). Sequencing PCR involved 25 cycles, each cycle 
consisting of 96 °C for 10 s, 50 °C for 5 s and 60 °C for 4 min.
Deep pyrosequencing of the HVR1 region
Forty-three samples from patients infected with HCV genotype 1 (HCV-1) and six from 
patients with HCV genotype 2 (HCV-2) were used for quasispecies analysis. This subset 
was analysed using the next-generation sequencing technology (454/Roche GS FLX 
platform) on the HVR1 region of the genome. The junction E1/E2 region (309 nt), which 
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contains the HVR1 region, was amplified using the nested PCR protocol described in 
Ramachandran et al. (2008). Each sample was amplified independently with fusion primers 
including the 454-primer key (A and B for forward and reverse primers, respectively), a 
different multiple identifier (MID) for each sample and HCV-specific sequence. The PCR 
products were purified using Agentcourt AmPure XP (Beckman Coulter). The quality of the 
amplicons was assessed using 3100 bioanalyser (Agilent Technologies). Purified amplicons 
were quantified using the Quan-iT PicoGreen dsDNA assay kit (Invitrogen). PCR amplicons 
were mixed at equimolar concentrations and diluted to a final concentration of 107 
molecules ml−1 prior to being subjected to emulsion (em)PCR, which was performed 
following the instructions supplied with the kit and enriched beads were subjected to 
pyrosequencing (titanium chemistry) using the 454/ Roche GS FLX instrument. The original 
sequence reads (raw data) were processed using the SFFFILE tools. Sequence reads 
belonging to each sample were identified and separated using MID. Low quality reads were 
removed. The pyrosequencing files were post-processed with the empirical threshold (ET) 
error correction algorithm (Skums et al., 2011), which shows very high accuracy in finding 
true haplotypes, removing false haplotypes and estimating the frequency of true ones. The 
ET algorithm includes a calibration step using sequence reads from single-clone HVR1 
samples, estimating an empirical frequency threshold for indels and haplotypes, and also 
correcting homopolymer errors using sequence alignment (Skums et al., 2011).
Phylogenetic analysis
Preliminary sequence analysis was conducted using SeqMan and MEGALIGN programs 
from the Lasergene DNA and Protein analysis software (version 8.0, DNASTAR Inc.). The 
Accelrys GCG Package (Genetic Computer Group, version 11.1-UNIX, Accelrys Inc.) was 
used for further analysis. Nucleotide sequences were aligned using the GCG multiple 
alignment program PILEUP. HCV genotypes/subgenotypes were classified based on the 
NS5b sequence (Smith et al., 1997) and by comparing each sequence with published 
reference sequences from GenBank. Initial phylogenetic trees were built using the Kimura 
two-parameter model of nucleotide substation (Tamura et al., 2004). Phylogenetic trees 
were constructed using the maximum-likelihood algorithm implemented in DNAML 
(PHYLIP package, v.3.6). Bootstrap values were calculated using 1000 replicates.
All sequences generated in this study were further subjected to phylogenetic analysis 
together with published sequences (NS5b region) from West and Central Africa retrieved 
from GenBank (Table 1).
Estimation of evolutionary dates and demographic history
The date of the MRCA of HCV strains from Nigeria was calculated using 362 nt NS5b 
sequences from the two villages. These sequences belong to genotypes 1 (n=51) and 2 
(n=9). Divergence times were calculated using BEAST (ver. 1.6.0) (Drummond & Rambaut, 
2007). The GTR substitution model was used with four gamma categories and invariant 
sites. Codons were partitioned into three partitions with unlinked substitution model and 
unlinked rate heterogeneity model across the codon partitions. Each sequence alignment was 
analysed with a strict or relaxed clock with an initial estimate for the rate of substitution as 
5×10−4 (Njouom et al., 2007). Constant size, exponential and expansion growth priors were 
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used. All models were run until the effective sample size for each was greater than 200. In 
order to compare the models the Bayes factor was estimated using importance sampling of 
the posterior probability (Newton et al., 1994). The exponential substitution model with an 
expansion growth prior was chosen because it had the largest Bayes factor; however, none 
of the models tested was found to be superior to any other model.
BSP analysis was done by segregating the NS5b sequences into the genotypes 1 (n=51) and 
2 (n=9) groups. Each dataset was analysed separately using BEAST (ver. 1.6.0) (Drummond 
& Rambaut, 2007) with a strict clock, a substitution rate of 5×10−4 and a piecewise-constant 
skyline model with six groups.
Population dynamics of HCV in West and Central Africa
Unbiased estimates of nucleotide diversity were calculated according to Nei (1987) using 
the program ARLEQUIN (Excoffier et al., 2005). Fu’s Fs test for detecting population 
growth, was calculated using ARLEQUIN (Excoffier et al., 2005). A P-value of 0.05 or less 
was considered statistically significant.
Nucleotide sequence accession numbers
Sequences from Nigeria reported in this study have been deposited in the National Center 
for Biotechnology Information database and can be retrieved under accession numbers 
JQ679028–JQ679087.
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Phylogenetic maximum-likelihood tree constructed using NS5b sequences (300 nt). 
Sequences determined in this study are shown in red. HCV genotypes are indicated on the 
branches. Reference sequences were obtained from the GenBank database and are shown in 
black. Bootstrap values higher than 60 % are indicated at the major nodes.
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Phylogenetic tree (maximum-likelihood) constructed using NS5b sequences from West and 
Central Africa. Sequences from Central Africa are shown by unfilled squares, while those 
from West Africa are shown by black triangles. The sequences from this study are marked 
by black circles. Bootstrap values higher than 60 % are indicated at the major nodes.
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Maximum-likelihood tree of intra-host HVR1 variants identified in 43 individuals infected 
with HCV genotypes 1. All sequences from a single individual are shown using the sample 
identification code. The three samples that share variants have been identified with same 
colours. Dotted circles represent members of the same family. Bootstrap values higher than 
60 % are indicated at the major nodes.
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Maximum-likelihood tree of intra-host HVR1 variants identified in six individuals infected 
with HCV genotypes 1. All sequences from a single individual are shown using the sample 
identification code and same colour. Dotted circle represent members of the same family. 
Bootstrap values higher than 60 % are indicated at the major nodes.
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BSP showing the epidemic history estimated for HCV genotype 1 variants from the Nigerian 
communities. The middle black line is the estimated mean of effective population size 
(logarithmic scale), while the grey lines show the limits of the 95 % highest posterior 
probability density for this estimate. The most recent time is the time of collection for the 
Nigerian sequences (2007) and the leftmost extent of the estimated effective population size 
is set at the estimated mean for the tMRCA for all the sequences. Time is shown using 
common era dating.
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BSP showing the epidemic history estimated for HCV genotype 2 variants from the Nigerian 
communities. The middle black line is the estimated mean of effective population size 
(logarithmic scale), while the grey lines show the limits of the 95 % highest posterior 
probability density for this estimate. The most recent time is the time of collection for the 
Nigerian sequences (2007) and the leftmost extent of the estimated effective population size 
is set at the estimated mean for the tMRCA for all the sequences. Time is shown using 
common era dating.
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Table 1
GenBank sequences used in this study
Region Reference Origin n GenBank accession nos
Central Africa (HCV-1) Ndjomou et al. 
(2003)
Cameroon 15 AY257069, AY257071, AY257073, AY257074, 
AY257077, AY257083, AY257086, AY257087, 
AY257090, AY257091, AY257092, AY257094, 
AY257095, AY257096, AY257102
Pasquier et al. (2005) Cameroon 57 AY632093, AY632094, AY632083, AY632084, 
AY632085, AY632087, AY632088, AY632089, 
AY632091, AY632092, AY632095, AY632096, 
AY632097, AY632098, AY632099, AY632100, 
AY632101, AY632102, AY632103, AY632104, 
AY632105, AY632106, AY632107, AY632109, 
AY632110, AY632111, AY632113, AY632114, 
AY632116, AY632117, AY632118, AY632119, 
AY632120, AY632121, AY632124, AY632125, 
AY632126, AY632127, AY632128, AY632130, 
AY632131, AY632132, AY632133, AY632137, 
AY632138, AY632139, AY632140, AY632141, 
AY632142, AY632144, AY632145, AY632146, 
AY632148, AY632149, AY632150, AY632151, 
AY632152
Njouom et al. (2005) Cameroon 7 AY685015, AY685034, AY685035, AY685044, 
AY685049, AY685050, AY685051
Stuyver et al. (1995) Cameroon 1 L38361
Bracho et al. (2006) Equatorial Guinea 1 AJ851228
West Africa (HCV-1) Jeannel et al. (1998) Benin 2 AF037230, AF037231
Jeannel et al. (1998) Burkina Faso 4 AF037232, AF037233, AF037234, AF037238
Jeannel et al. (1998) Guinea 2 AF037235, AF037237
Candotti et al. (2003) Ghana 2 AY236369, AY236370
Central Africa (HCV-2) Njouom et al. (2009) Central African Republic 4 FJ791099, FJ791094, FJ791088, FJ791087
Njouom et al. (2005) Cameroon 35 AY685048, AY685043, AY685041, AY685040, 
AY685037, AY685033, AY685029, AY685022, 
AY685018, AY632179, AY632178, AY632177, 
AY632176, AY632175, AY632174, AY632173, 
AY632172, AY632171, AY632170, AY632169, 
AY632168, AY632167, AY632166, AY632165, 
AY632164, AY632163, AY632162, AY632161, 
AY632160, AY632159, AY632158, AY632154, 
AY632156, AY632155, AY632157
Njouom et al. (2005) Cameroon 13 AY265451, AY265449, AY265444, AY265443, 
AY265442, AY265437, AY265436, AY265433, 
AY265427, AY265426, AY265423, AY265422, 
AY265420
Ndjomou et al. 
(2003)
Cameroon 8 AY257100, AY257099, AY257088, AY257084, 
AY257081, AY257080, AY257079, AY257076
West Africa (HCV-2) Candotti et al. (2003) Ghana 19 AY236381, AY236367, AY236368, AY236371, 
AY236372, AY236373, AY236374, AY236375, 
AY236376, AY236377, AY236378, AY236379, 
AY236380, AY236382, AY236383, AY236384, 
AY236385, AY236386, AY236387
Jeannel et al. (1998) Burkina Faso 10 AF037240, AF037245, AF037246, AF037248, 
AF037249, AF037250, AF037251, AF037252, 
AF037253, AF037254
Jeannel et al. (1998) Benin 4 AF037239, AF037241, AF037242, AF037244
Jeannel et al. (1998) Guinea 1 AF037247
Markov et al. (2009) Guinea-Bissau 56 GQ153856, GQ153857, GQ153858, GQ153859, 
GQ153860, GQ153861, GQ153862, GQ153863, 
GQ153864, GQ153865, GQ153866, GQ153867, 
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Region Reference Origin n GenBank accession nos
GQ153868, GQ153869, GQ153870, GQ153871, 
GQ153872, GQ153873, GQ153874, GQ153875, 
GQ153876, GQ153877, GQ153878, GQ153879, 
GQ153880, GQ153881, GQ153882, GQ153883, 
GQ153884, GQ153885, GQ153886, GQ153887, 
GQ153888, GQ153889, GQ153890, GQ153891, 
GQ153892, GQ153893, GQ153894, GQ153895, 
GQ153896, GQ153897, GQ153898, GQ153899, 
GQ153900, GQ153901, GQ153902, GQ153903, 
GQ153904, GQ153905, GQ153906, GQ153907, 
GQ153908, GQ153909, GQ153910, GQ153911
Ruggieri et al. 
(1996)
Guinea 5 X93323, X93324, X93325, X93326, X93327
Mellor et al. (1995) Gambia 2 U31268, U31269
*
HCV-1, HCV genotype 1, HCV-2, HCV genotype 2.
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